Search Results
Results found for "Domain Therapeutics"
- Using Live-cell High-Content Screening to Characterize CB2 Ligands: Insights From 16 Synthetic Cannabinoids
Despite its therapeutic potential, CB2 pharmacology remains difficult to interrogate with confidence.
- 📰 GPCR Weekly News, February 19 to 25, 2024
GPCR Binders, Drugs, and more Advances in structure-based drug design: The potential for precision therapeutics
- A robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery.
crystal structures of both CBRs.[4–8] A key challenge in CBR modulator development is separating the therapeutic New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders.
- Fluorescence based HTS compatible ligand binding assays for dopamine D3 receptors in baculovirus preparations and live cells
have been approved as drugs, however they often have serious side effects and too low or temporary therapeutic Pharmacology & Therapeutics 2016 , 165 , 164–177. https://doi.org/10.1016/j.pharmthera.2016.06.007
- Hear the sounds: the role of G protein-coupled receptors in the cochlea
Frizzleds and Lgrs are dominant GPCRs that regulate stem cell self-renew abilities.
- Feeder or trigger – CCR2 as a scavenger and regulator of cell migration
This scavenging function should be considered when evaluating the safety and therapeutic efficacy of
- Scientific Isolation: The Real Reason Early Biotechs Lose Traction
Pattern: Scientific Isolation Scientific Isolation = when a biotech’s internal activity becomes so dominated
- Why Kinetics Matter More Than Kd in GPCR Drug Discovery
Identify emerging targets: Allosteric modulators, biased ligands, and kinetic frameworks will dominate
